Clinical trials of TAA-directed cancer vaccines
TAAs | Disease | Vaccine intervention | Trial number | Phase | Status | Locations |
---|---|---|---|---|---|---|
HER2 | Breast cancer | AdHER2/neu dendritic cell vaccine | NCT01730118 | Phase 1 | Completed | National Institutes of Health Clinical Center |
MUC1 | Lung carcinoma | MUC1 Peptide-Poly-ICLC Vaccine | NCT03300817 | Phase 1 | Recruiting | Mayo Clinic in Rochester/University of Pittsburgh Cancer Institute |
Survivin | Recurrent epithelial ovarian cancer | DC-006 vaccine | NCT01334047 | Phase 1/2 | Terminated | Oslo University Hospital-Norwegian Radium Hospital |
hTERT | Metastatic prostate cancer | hTERT mRNA DC | NCT01153113 | Phase 1/2 | Withdrawn | University of Florida |
NY-ESO-1 | Prostate cancer/bladder cancer/non-small cell lung cancer | NY-ESO-1 plasmid DNA Cancer Vaccine | NCT00199849 | Phase 1 | Completed | New York Presbyterian Hospital/UT MD Anderson Cancer Center Houston |
MAGE-A3 | Squamous cell carcinoma of the head and neck | HPV-16 vaccine/MAGE-A3 | NCT00257738 | Phase 1 | Completed | University of Maryland School of Medicine Baltimore |
Tyrosinase | Melanoma | Montanide ISA 51 | NCT00184067 | Phase 2 | Terminated | USC/Norris Comprehensive Cancer Center |
gp100 | Melanoma | gp100 human melanoma peptide vaccine | NCT00001439 | Phase 1 | Completed | National Cancer Institute |
MART-1 | Malignant melanoma | CYT004-MelQbG10 | NCT00306566 | Phase 1/2 | Completed | Centre Pluridisciplinaire d’Oncologie & LICR |